title: Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
abstract: One promise of new translational safety biomarkers (TSBs) is their ability to demonstrate that toxicities in animal studies are monitorable at an early stage, such that human relevance of potential adverse effects of drugs can be safely and definitively evaluated in clinical trials. Another is that they would provide an earlier, more definitive and deeper insight to patient prognosis compared with conventional biomarkers. Recent experience with regulatory authorities indicates that resource demands for new TSB qualifications under the current framework are daunting and the rate of their expansion will be slow, particularly in light of mounting financial pressures on the pharmaceutical industry. Sponsors face a dilemma over engaging in safety biomarker qualification consortia. While it is clear new TSBs could be considered catalysts to drug development and that patient health, business and scientific benefits, described here using examples, should outweigh qualification costs, concerns exist that early ambiguities in biomarker interpretations at the introduction of such new TSBs might hinder drug development.
authors.affiliation: Safety Assessment & Laboratory Animal Resources, Merck and Co., Inc., West Point, PA 19486-0004, USA. frank_sistare@merck.com.
authors.forename: Frank D
authors.initials: FD
authors.lastname: Sistare
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: DeGeorge
mesh_terms: D000818:Animals; D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000191:economics; D004345:Drug Industry / Q000191:economics; D064420:Drug-Related Side Effects and Adverse Reactions; D033161:Government Regulation; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics; D051381:Rats
chemical_list: D054316:Biomarkers, Pharmacological; D004364:Pharmaceutical Preparations